RADX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Radiopharm Theranostics Ltd (RADX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising developments in its Phase 2b study and analysts have raised price targets, the technical indicators show a bearish trend, and there is no significant trading sentiment or recent news to act as a catalyst. Given the lack of immediate positive momentum and the investor's preference for long-term stability, holding off on buying for now is recommended.
The MACD is negative and expanding, RSI is neutral at 21.295, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels (Pivot: 5.041, S1: 4.695). Overall, the technical indicators suggest a bearish trend.
due to positive interim Phase 2b data for RAD101 in brain metastases, with 92% MRI concordance. The company is addressing a $500M market opportunity in brain metastasis diagnostics.
The stock is in a bearish technical trend with no recent news or significant trading activity from hedge funds, insiders, or Congress. Additionally, the pre-market price dropped by -4.71%.
No financial data available for analysis.
Analysts maintain a 'Buy' rating with raised price targets ($15 and $16) due to promising interim Phase 2b data for RAD101. However, final data is expected in 2026, indicating a longer timeline for potential catalysts.
